Rigel Pharmaceuticals Archives -

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new

Lilly cuts a $960m deal with Rigel on RIP kinase

https://pharmaphorum.com/news/lilly-cuts-a-960m-deal-with-rigel-on-rip-kinase/

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the

Sobi gets EU nod for Doptelet in rare blood disorder ITP

https://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

https://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/

The EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

https://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/

Rigel Pharmaceuticals